Zolmitriptan (BioDeep_00000003193)

human metabolite blood metabolite Chemicals and Drugs

代谢物信息卡片

(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one

化学式: C16H21N3O2 (287.1634)
中文名称: 佐米曲坦
谱图信息: 最多检出来源 Homo sapiens(natural_products) 4.62%

分子结构信息

SMILES: CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3
InChI: InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1

描述信息

Zolmitriptan is only found in individuals that have used or taken this drug. It is a synthetic tryptamine derivative and appears as a white powder that is readily soluble in water. [Wikipedia]Zolmitriptan binds with high affinity to human 5-HT_1B and 5-HT_1D receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
N - Nervous system > N02 - Analgesics > N02C - Antimigraine preparations > N02CC - Selective serotonin (5ht1) agonists
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists
C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist
D000890 - Anti-Infective Agents > D023303 - Oxazolidinones

同义名列表

20 个代谢物同义名

(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one; (4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one; 4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone; 4-[[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one; AstraZeneca brand OF zolmitriptan; Zeneca brand OF zolmitriptan; Ferrer brand OF zolmitriptan; Astra brand OF zolmitriptan; Zolmitriptan-d6; Zolmitriptanum; Zolmitriptan; Zomigoro; AscoTop; Zominat; Zipton; Flezol; 311c90; Zomig; ZMT; Zolmitriptan

数据库引用编号

17 个数据库交叉引用编号

ChEBI: CHEBI:10124
KEGG: C07218
KEGGdrug: D00415
PubChem: 60857
PubChem: 5731
HMDB: HMDB0014460
Metlin: METLIN44026
DrugBank: DB00315
ChEMBL: CHEMBL1185
Wikipedia: Zolmitriptan
chemspider: 54844
CAS: 139264-25-8
CAS: 139264-17-8
PMhub: MS000008463
PubChem: 9427
NIKKAJI: J694.097H
KNApSAcK: 10124

分类词条

Tryptamines and derivatives

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

9606 - Homo sapiens: -

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位		关联基因列表
Cytoplasm	8	ABCB1, BCL2, BCL2L1, CASP3, CASP9, CYP2D6, NOS3, S100A12
Peripheral membrane protein	2	CYP1B1, S100A12
Endoplasmic reticulum membrane	4	BCL2, CYP1A2, CYP1B1, CYP2D6
Mitochondrion membrane	2	BCL2L1, MAOA
Nucleus	6	BCL2, CASP3, CASP9, FOS, NOS3, S100A12
cytosol	8	BCL2, BCL2L1, CASP3, CASP9, FOS, MAOA, NOS3, S100A12
dendrite	2	HTR1D, HTR1F
centrosome	1	BCL2L1
nucleoplasm	3	CASP3, FOS, NOS3
RNA polymerase II transcription regulator complex	1	FOS
Cell membrane	5	ABCB1, HTR1D, HTR1F, S100A12, SLCO1A2
Cytoplasmic side	2	BCL2L1, MAOA
Multi-pass membrane protein	6	ABCB1, CACNA1I, HTR1D, HTR1F, NNT, SLCO1A2
Synapse	3	HTR1D, HTR1F, TAC1
cell surface	1	ABCB1
glutamatergic synapse	2	C1QL3, CASP3
Golgi apparatus	1	NOS3
Golgi membrane	1	NOS3
mitochondrial inner membrane	2	BCL2L1, NNT
neuronal cell body	2	CASP3, TAC1
Cytoplasm, cytosol	1	BCL2L1
plasma membrane	7	ABCB1, CACNA1I, HTR1D, HTR1F, NOS3, S100A12, SLCO1A2
synaptic vesicle membrane	1	BCL2L1
Membrane	8	ABCB1, BCL2, CACNA1I, CYP1B1, CYP2D6, MAOA, NNT, SLCO1A2
apical plasma membrane	2	ABCB1, SLCO1A2
axon	1	TAC1
basolateral plasma membrane	1	SLCO1A2
caveola	1	NOS3
extracellular exosome	1	ABCB1
endoplasmic reticulum	4	BCL2, BCL2L1, CYP2D6, FOS
extracellular space	1	TAC1
perinuclear region of cytoplasm	1	NOS3
mitochondrion	7	BCL2, BCL2L1, CASP9, CYP1B1, CYP2D6, MAOA, NNT
protein-containing complex	2	BCL2, CASP9
intracellular membrane-bounded organelle	3	CYP1A2, CYP1B1, CYP2D6
Microsome membrane	3	CYP1A2, CYP1B1, CYP2D6
postsynaptic density	1	CASP3
Secreted	3	C1QL3, S100A12, VIP
extracellular region	3	S100A12, TAC1, VIP
Mitochondrion outer membrane	3	BCL2, BCL2L1, MAOA
Single-pass membrane protein	4	BCL2, BCL2L1, CYP2D6, MAOA
mitochondrial outer membrane	3	BCL2, BCL2L1, MAOA
hippocampal mossy fiber to CA3 synapse	1	C1QL3
Mitochondrion matrix	1	BCL2L1
mitochondrial matrix	1	BCL2L1
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome	1	BCL2L1
Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane	1	BCL2L1
Nucleus membrane	2	BCL2, BCL2L1
Bcl-2 family protein complex	2	BCL2, BCL2L1
nuclear membrane	2	BCL2, BCL2L1
Cytoplasm, P-body	1	NOS3
P-body	1	NOS3
Apical cell membrane	1	ABCB1
Mitochondrion inner membrane	1	NNT
Matrix side	1	NNT
pore complex	1	BCL2
Cytoplasm, cytoskeleton	1	S100A12
collagen trimer	1	C1QL3
neuron projection	1	VIP
chromatin	1	FOS
cytoskeleton	2	NOS3, S100A12
Cytoplasm, Stress granule	1	NOS3
cytoplasmic stress granule	1	NOS3
respiratory chain complex	1	NNT
myelin sheath	1	BCL2
basal plasma membrane	1	SLCO1A2
secretory granule lumen	1	S100A12
nuclear matrix	1	FOS
voltage-gated calcium channel complex	1	CACNA1I
endocytic vesicle membrane	1	NOS3
Single-pass type IV membrane protein	1	MAOA
apoptosome	1	CASP9
synaptic cleft	1	C1QL3
Basal cell membrane	1	SLCO1A2
protein-DNA complex	1	FOS
external side of apical plasma membrane	1	ABCB1
death-inducing signaling complex	1	CASP3
transcription factor AP-1 complex	1	FOS
BAD-BCL-2 complex	1	BCL2
caspase complex	1	CASP9
[Isoform Bcl-X(L)]: Mitochondrion inner membrane	1	BCL2L1

文献列表

Mai Ahmed Tawfik, Mai M Eltaweel, Michael M Farag, Hesham A Shamsel-Din, Ahmed B Ibrahim. Sonophoresis-assisted transdermal delivery of antimigraine-loaded nanolipomers: Radio-tracking, histopathological assessment and in-vivo biodistribution study. International journal of pharmaceutics. 2023 Sep; 644(?):123338. doi: 10.1016/j.ijpharm.2023.123338. [PMID: 37607646]
Sunena Jha, Dinanath Mishra. Evaluation of Brain Targeting Potential of Zolmitriptan Mucoadhesive Nanoparticles for Intranasal Drug Delivery. Pharmaceutical nanotechnology. 2022; 10(2):113-124. doi: 10.2174/2211738510666220303160414. [PMID: 35240970]
Lingling Han, Yudi Jia, Yanjia Zhao, Chen Sun, Min Zhao, Ying Peng, Jiang Zheng. Metabolic activation of zolmitriptan mediated by CYP2D6. Xenobiotica; the fate of foreign compounds in biological systems. 2021 Nov; 51(11):1292-1302. doi: 10.1080/00498254.2021.1938290. [PMID: 34096834]
Pakinaz Y Khashaba, Azza H Rageh, Noha N Atia, Sally A El Zohny. Vortex-assisted dispersive solid phase microextraction using Fe3O4/FeOOH magnetic nanocomposites for high-performance thin-layer chromatographic determination of zolmitriptan in rabbit plasma samples. Journal of chromatography. A. 2021 Aug; 1651(?):462276. doi: 10.1016/j.chroma.2021.462276. [PMID: 34107401]
Randa Hanie Awadeen, Mariza Fouad Boughdady, Mahasen Mohamed Meshali. Quality by Design Approach for Preparation of Zolmitriptan/Chitosan Nanostructured Lipid Carrier Particles - Formulation and Pharmacodynamic Assessment. International journal of nanomedicine. 2020; 15(?):8553-8568. doi: 10.2147/ijn.s274352. [PMID: 33173292]
Jason Barricklow, Joseph Tweed, Christopher L Holliman, Ragu Ramanathan. Evaluation of OptiFlow™-MS/MS for bioanalysis of pharmaceutical drugs and metabolites. Bioanalysis. 2020 Jan; 12(1):23-34. doi: 10.4155/bio-2019-0250. [PMID: 31849261]
Farshid Ali Naghi Zadeh Khezri, C S R Lakshmi, Rama Bukka, Malviya Nidhi, Shachindra L Nargund. Pharmacokinetic study and brain tissue analysis of Zolmitriptan loaded chitosan nanoparticles in rats by LC-MS method. International journal of biological macromolecules. 2020 Jan; 142(?):52-62. doi: 10.1016/j.ijbiomac.2019.08.236. [PMID: 31593739]
Vimal Maurya, Pranesh Kumar, Sreemoyee Chakraborti, Ashok K Singh, Archana S Bhadauria, Umesh Kumar, Dinesh Kumar, Arnab Pramanik, Biswajit Saha, Venkatesh Kumar R, Sunil Babu Gosipatala, Bolay Bhattachariya, Biswanath Maity, Sudipta Saha. Zolmitriptan attenuates hepatocellular carcinoma via activation of caspase mediated apoptosis. Chemico-biological interactions. 2019 Aug; 308(?):120-129. doi: 10.1016/j.cbi.2019.05.033. [PMID: 31129132]
Yamato Sano, Tadahaya Mizuno, Tatsuki Mochizuki, Yasuo Uchida, Mina Umetsu, Tetsuya Terasaki, Hiroyuki Kusuhara. Evaluation of Organic Anion Transporter 1A2-knock-in Mice as a Model of Human Blood-brain Barrier. Drug metabolism and disposition: the biological fate of chemicals. 2018 11; 46(11):1767-1775. doi: 10.1124/dmd.118.081877. [PMID: 30154106]
Wangda Zhou, Jianguo Li, Bruce Birmingham, Hongmei Xu, Stefan Lillieborg, Diansong Zhou, Nidal Al-Huniti. Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine. Journal of clinical pharmacology. 2017 10; 57(10):1258-1267. doi: 10.1002/jcph.935. [PMID: 28581633]
Harilal Patel, Prakash Patel, Nirav Modi, Shaival Shah, Ashok Ghoghari, Bhavesh Variya, Ritu Laddha, Dipesh Baradia, Nitin Dobaria, Pavak Mehta, Nuggehally R Srinivas. One should avoid retro-orbital pharmacokinetic sample collections for intranasal dosing in rats: Illustration of spurious pharmacokinetics generated for anti-migraine drugs zolmitriptan and eletriptan. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2017 Aug; 106(?):87-93. doi: 10.1016/j.ejps.2017.05.044. [PMID: 28549679]
Kun Han, Si-jie Lu, Su Zeng, Lu-shan Yu. [Induction study of CYP3A2 in male rats by zolmitriptan]. Yao xue xue bao = Acta pharmaceutica Sinica. 2017 Jan; 52(1):44-50. doi: NULL. [PMID: 29911377]
Tabassum Khan, Rajeev Ranjan, Yeshwant Dogra, Sanketkumar M Pandya, Hasham Shafi, S K Singh, Prem N Yadav, Amit Misra. Intranasal Eutectic Powder of Zolmitriptan with Enhanced Bioavailability in the Rat Brain. Molecular pharmaceutics. 2016 09; 13(9):3234-40. doi: 10.1021/acs.molpharmaceut.6b00453. [PMID: 27518323]
Bhargav Patel, B N Suhagia, Arvind G Jangid, Hiren N Mistri, Nirmal Desai. Systematic evaluation of matrix effect and cross-talk-free method for simultaneous determination of zolmitriptan and N-desmethyl zolmitriptan in human plasma: a sensitive LC-MS/MS method validation and its application to a clinical pharmacokinetic study. Biomedical chromatography : BMC. 2016 Mar; 30(3):447-58. doi: 10.1002/bmc.3568. [PMID: 26189757]
Kentaro Tokuoka, Risa Takayanagi, Yuji Suzuki, Masayuki Watanabe, Yasuhisa Kitagawa, Yasuhiko Yamada. Theory-based analysis of clinical efficacy of triptans using receptor occupancy. The journal of headache and pain. 2014 Dec; 15(?):85. doi: 10.1186/1129-2377-15-85. [PMID: 25488888]
Mamdouh R Rezk, Adel M Michael, Hayam M Lotfy, Ayman O El-Kadi, Mostafa A Shehata. A rapid and sensitive HPLC assay of some concomitant anti-migraine drugs. Journal of chromatographic science. 2014 Aug; 52(7):704-6. doi: 10.1093/chromsci/bmt103. [PMID: 23845885]
Stewart J Tepper, Susy Chen, Faith Reidenbach, Alan M Rapoport. Intranasal zolmitriptan for the treatment of acute migraine. Headache. 2013 Sep; 53 Suppl 2(?):62-71. doi: 10.1111/head.12181. [PMID: 24024604]
Katarina Varnäs, Aurelija Jučaite, Dennis J McCarthy, Per Stenkrona, Magdalena Nord, Christer Halldin, Lars Farde, Stephen Kanes. A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers. Cephalalgia : an international journal of headache. 2013 Jul; 33(10):853-60. doi: 10.1177/0333102413476372. [PMID: 23430984]
Ji Liu, Xiao Zhou. Determination of zolmitriptan and its primary metabolite, n-desmethy-zolmitriptan, in rat plasma by LC-MS-MS. Journal of chromatographic science. 2013 Jan; 51(1):59-64. doi: 10.1093/chromsci/bms106. [PMID: 22722326]
M Cánovas, M Canals, F Polonio, F Cabré. Bioequivalence study of 2 orodispersible formulations of zolmitriptan 5 mg in healthy volunteers. Arzneimittel-Forschung. 2012 Oct; 62(10):482-6. doi: 10.1055/s-0032-1321848. [PMID: 22918855]
Azza A Mahmoud, Salwa Salah. Fast relief from migraine attacks using fast-disintegrating sublingual zolmitriptan tablets. Drug development and industrial pharmacy. 2012 Jun; 38(6):762-9. doi: 10.3109/03639045.2011.625949. [PMID: 22023340]
Chaoqun Yu, Pengfei Gu, Wenjun Zhang, Cuifang Cai, Haibing He, Xing Tang. Evaluation of submicron emulsion as vehicles for rapid-onset intranasal delivery and improvement in brain targeting of zolmitriptan. Drug delivery. 2011 Nov; 18(8):578-85. doi: 10.3109/10717544.2011.600784. [PMID: 21838542]
B Uslu, D Canbaz. Anodic voltammetry of zolmitriptan at boron-doped diamond electrode and its analytical applications. Die Pharmazie. 2010 Apr; 65(4):245-50. doi: NULL. [PMID: 20432618]
Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance. Journal of medicinal chemistry. 2009 Aug; 52(15):4844-52. doi: 10.1021/jm900403j. [PMID: 19445515]
Marjo J Karjalainen, Pertti J Neuvonen, Janne T Backman. In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic & clinical pharmacology & toxicology. 2008 Aug; 103(2):157-65. doi: 10.1111/j.1742-7843.2008.00252.x. [PMID: 18816299]
R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
B Lee Peterlin, Alan M Rapoport. Clinical pharmacology of the serotonin receptor agonist, zolmitriptan. Expert opinion on drug metabolism & toxicology. 2007 Dec; 3(6):899-911. doi: 10.1517/17425255.3.6.899. [PMID: 18028032]
Sarah Malacarne, Solange Moll, Karine Hadaya, Léo Buhler, Pierre-Yves Martin. Renal ischaemic injuries during the use of zolmitriptan for treatment of migraines in a transplanted patient under tacrolimus therapy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2007 Nov; 22(11):3341-3. doi: 10.1093/ndt/gfm476. [PMID: 17631510]
Vikramjit S Kanwar, Jennifer Pearce. Acute renal failure in a 17-year-old female with ALL receiving escalating intravenous methotrexate without leukovorin. Pediatric blood & cancer. 2007 Aug; 49(2):216;author reply 219. doi: 10.1002/pbc.20940. [PMID: 16786587]
Xiaoyan Chen, Dan Liu, Yan Luan, Fengdan Jin, Dafang Zhong. Determination of zolmitriptan in human plasma by liquid chromatography-tandem mass spectrometry method: application to a pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2006 Feb; 832(1):30-5. doi: 10.1016/j.jchromb.2005.12.008. [PMID: 16413836]
Mats Bergström, Roger Yates, Anders Wall, Matts Kågedal, Stina Syvänen, Bengt Långström. Blood-brain barrier penetration of zolmitriptan--modelling of positron emission tomography data. Journal of pharmacokinetics and pharmacodynamics. 2006 Feb; 33(1):75-91. doi: 10.1007/s10928-005-9001-1. [PMID: 16402287]
Peter J Goadsby, Roger Yates. Zolmitriptan intranasal: a review of the pharmacokinetics and clinical efficacy. Headache. 2006 Jan; 46(1):138-49. doi: 10.1111/j.1526-4610.2006.00301.x. [PMID: 16412161]
Jessica A Fulton, Jason Kahn, Lewis S Nelson, Robert S Hoffman. Renal infarction during the use of rizatriptan and zolmitriptan: two case reports. Clinical toxicology (Philadelphia, Pa.). 2006; 44(2):177-80. doi: 10.1080/15563650500514574. [PMID: 16615676]
R Yates, J Sörensen, M Bergström, G Antoni, K Nairn, J Kemp, B Långström, A Dane. Distribution of intranasal C-zolmitriptan assessed by positron emission tomography. Cephalalgia : an international journal of headache. 2005 Dec; 25(12):1103-9. doi: 10.1111/j.1468-2982.2005.00966.x. [PMID: 16305598]
David B Wainscott, Joseph H Krushinski, James E Audia, John M Schaus, John M Zgombick, Virginia L Lucaites, David L Nelson. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. I. In vitro characterization of binding properties. Naunyn-Schmiedeberg's archives of pharmacology. 2005 Mar; 371(3):169-77. doi: 10.1007/s00210-005-1035-9. [PMID: 15900510]
Anders Wall, Matts Kågedal, Mats Bergström, Eva Jacobsson, Dag Nilsson, Gunnar Antoni, Pernilla Frändberg, Sven-Ake Gustavsson, Bengt Långström, Roger Yates. Distribution of zolmitriptan into the CNS in healthy volunteers: a positron emission tomography study. Drugs in R&D. 2005; 6(3):139-47. doi: 10.2165/00126839-200506030-00002. [PMID: 15869317]
Zunjian Zhang, Fengguo Xu, Yuan Tian, Wei Li, Guoguang Mao. Quantification of zolmitriptan in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2004 Dec; 813(1-2):227-33. doi: 10.1016/j.jchromb.2004.09.043. [PMID: 15556537]
Hisaka Igarashi. [Side effects of triptans]. No to shinkei = Brain and nerve. 2004 Sep; 56(9):754-9. doi: ". [PMID: 15552864]
Jun Chen, Xin-Guo Jiang, Wen-Ming Jiang, Ni Mei, Xiao-Ling Gao, Qi-Zhi Zhang. High-performance liquid chromatographic analysis of zolmitriptan in human plasma using fluorescence detection. Journal of pharmaceutical and biomedical analysis. 2004 May; 35(3):639-45. doi: 10.1016/j.jpba.2004.01.019. [PMID: 15137991]
U Reuter, S Salomone, G W Ickenstein, C Waeber. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia : an international journal of headache. 2004 May; 24(5):398-407. doi: 10.1111/j.1468-2982.2004.00683.x. [PMID: 15096229]
Nick Syrett, Susan Abu-Shakra, Roger Yates. Zolmitriptan nasal spray: advances in migraine treatment. Neurology. 2003 Oct; 61(8 Suppl 4):S27-30. doi: 10.1212/wnl.61.8_suppl_4.s27. [PMID: 14581655]
David C Evans, Desmond O'Connor, Brian G Lake, Raymond Evers, Christopher Allen, Richard Hargreaves. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug metabolism and disposition: the biological fate of chemicals. 2003 Jul; 31(7):861-9. doi: 10.1124/dmd.31.7.861. [PMID: 12814962]
Roger Yates, Kevin Nairn, Ruth Dixon, Emma Seaber. Preliminary studies of the pharmacokinetics and tolerability of zolmitriptan nasal spray in healthy volunteers. Journal of clinical pharmacology. 2002 Nov; 42(11):1237-43. doi: 10.1177/009127002762491325. [PMID: 12412822]
Roger Yates, Kevin Nairn, Ruth Dixon, J V Kemp, A L Dane. Pharmacokinetics, dose proportionality, and tolerability of single and repeat doses of a nasal spray formulation of zolmitriptan in healthy volunteers. Journal of clinical pharmacology. 2002 Nov; 42(11):1244-50. doi: 10.1177/009127002762491334. [PMID: 12412823]
R A Yates, M Tateno, K Nairn, A Ikegami, A Dane, J Kemp. The pharmacokinetics of the antimigraine compound zolmitriptan in Japanese and Caucasian subjects. European journal of clinical pharmacology. 2002 Jul; 58(4):247-52. doi: 10.1007/s00228-002-0461-6. [PMID: 12136370]
E M Clement, M Franklin. Simultaneous measurement of zolmitriptan and its major metabolites N-desmethylzolmitriptan and zolmitriptan N-oxide in human plasma by high-performance liquid chromatography with coulometric detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2002 Jan; 766(2):339-43. doi: 10.1016/s0378-4347(01)00470-4. [PMID: 11824821]
K S Jandu, V Barrett, M Brockwell, D Cambridge, D R Farrant, C Foster, H Giles, R C Glen, A P Hill, H Hobbs, A Honey, G R Martin, J Salmon, D Smith, P Woollard, D L Selwood. Discovery of 4-[3-(trans-3-dimethylaminocyclobutyl)-1H-indol-5-ylmethyl]-(4S)-oxazolidin-2-one (4991W93), a 5HT(1B/1D) receptor partial agonist and a potent inhibitor of electrically induced plasma extravasation. Journal of medicinal chemistry. 2001 Mar; 44(5):681-93. doi: 10.1021/jm000956k. [PMID: 11262079]
M L Boshuisen, J A den Boer. Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder. Psychopharmacology. 2000 Sep; 152(1):74-9. doi: 10.1007/s002130000529. [PMID: 11041318]
F G Moeller, J M Bjork, D M Dougherty, L D Van de Kar, D M Marsh, A C Swann. Low dose zolmitriptan as a 5-HT neuroendocrine challenge agent in humans. Psychoneuroendocrinology. 2000 Aug; 25(6):607-18. doi: 10.1016/s0306-4530(00)00013-5. [PMID: 10840172]
D Deleu, Y Hanssens. Current and emerging second-generation triptans in acute migraine therapy: a comparative review. Journal of clinical pharmacology. 2000 Jul; 40(7):687-700. doi: 10.1177/00912700022009431. [PMID: 10883409]
K Vishwanathan, M G Bartlett, J T Stewart. Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. Rapid communications in mass spectrometry : RCM. 2000; 14(3):168-72. doi: 10.1002/(sici)1097-0231(20000215)14:3<168::aid-rcm861>3.0.co;2-9. [PMID: 10637423]
A D Van Haarst, J M Van Gerven, A F Cohen, M De Smet, A Sterrett, K L Birk, A L Fisher, M E De Puy, M R Goldberg, D G Musson. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers. British journal of clinical pharmacology. 1999 Aug; 48(2):190-6. doi: 10.1046/j.1365-2125.1999.00011.x. [PMID: 10417495]
R Whale, Z Bhagwagar, P J Cowen. Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors?. Psychopharmacology. 1999 Jul; 145(2):223-6. doi: 10.1007/s002130051052. [PMID: 10463324]
A M Hughes, R Dixon, A Dane, J Kemp, L Cummings, R A Yates. Effects of zolmitriptan (Zomig) on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in volunteers without migraine. Cephalalgia : an international journal of headache. 1999 Mar; 19(2):100-6; discussion 73. doi: 10.1046/j.1468-2982.1999.019002100.x. [PMID: 10214535]
R Dixon, K Engleman, J Kemp, J L Ruckle. A comparison of the pharmacokinetics and tolerability of the novel antimigraine compound zolmitriptan in adolescents and adults. Journal of child and adolescent psychopharmacology. 1999; 9(1):35-42. doi: 10.1089/cap.1999.9.35. [PMID: 10357516]
E J Seaber, R W Peck, D A Smith, J Allanson, N R Hefting, J J van Lier, F A Sollie, J Wemer, J H Jonkman. The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers. British journal of clinical pharmacology. 1998 Nov; 46(5):433-9. doi: 10.1046/j.1365-2125.1998.00809.x. [PMID: 9833595]
R Dixon, A M Hughes, K Nairn, M Sellers, J V Kemp, R A Yates. Effects of the antimigraine compound zolmitriptan ('Zomig') on psychomotor performance alone and in combination with diazepam in healthy volunteers. Cephalalgia : an international journal of headache. 1998 Sep; 18(7):468-75. doi: 10.1046/j.1468-2982.1998.1807468.x. [PMID: 9793699]
R Dixon, S French, J Kemp, M Sellers, V Leclerc, M Delvaux, J Rautureau. Effect of hepatic impairment on the pharmacokinetics of zolmitriptan. Journal of clinical pharmacology. 1998 Aug; 38(8):694-701. doi: 10.1002/j.1552-4604.1998.tb04808.x. [PMID: 9725544]
D A Smith, E W Cleary, S Watkins, C S Huffman, S C Dilzer, K C Lasseter. Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study. Journal of clinical pharmacology. 1998 Aug; 38(8):685-93. doi: 10.1002/j.1552-4604.1998.tb04807.x. [PMID: 9725543]
R W Peck, E J Seaber, R M Dixon, G R Layton, B C Weatherley, S H Jackson, P E Rolan, J Posner. The pharmacodynamics and pharmacokinetics of the 5HT1B/1D-agonist zolmitriptan in healthy young and elderly men and women. Clinical pharmacology and therapeutics. 1998 Mar; 63(3):342-53. doi: 10.1016/s0009-9236(98)90166-7. [PMID: 9542478]
A Proietti-Cecchini, J Afra, J Schoenen. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalgia : an international journal of headache. 1997 Dec; 17(8):849-54; discussion 799. doi: 10.1046/j.1468-2982.1997.1708849.x. [PMID: 9453273]
C Gillotin, C Bagnis, J P Mamet, R W Peck, G Deray. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis. International journal of clinical pharmacology and therapeutics. 1997 Nov; 35(11):522-6. doi: . [PMID: 9401835]
P Rolan. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia : an international journal of headache. 1997 Oct; 17 Suppl 18(?):21-7. doi: 10.1177/0333102497017s1804. [PMID: 9399014]
G R Martin. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia : an international journal of headache. 1997 Oct; 17 Suppl 18(?):4-14. doi: 10.1177/0333102497017s1802. [PMID: 9399012]
R Dixon, A Warrander. The clinical pharmacokinetics of zolmitriptan. Cephalalgia : an international journal of headache. 1997 Oct; 17 Suppl 18(?):15-20. doi: 10.1177/0333102497017s1803. [PMID: 9399013]
E Seaber, N On, R M Dixon, M Gibbens, W J Leavens, J Liptrot, G Chittick, J Posner, P E Rolan, R W Pack. The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90). British journal of clinical pharmacology. 1997 Jun; 43(6):579-87. doi: 10.1046/j.1365-2125.1997.00614.x. [PMID: 9205817]
G R Martin, A D Robertson, S J MacLennan, D J Prentice, V J Barrett, J Buckingham, A C Honey, H Giles, S Moncada. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan). British journal of pharmacology. 1997 May; 121(2):157-64. doi: 10.1038/sj.bjp.0701041. [PMID: 9154322]
M D Ferrari. 311C90: increasing the options for therapy with effective acute antimigraine 5HT1B/1D receptor agonists. Neurology. 1997 Mar; 48(3 Suppl 3):S21-4. doi: 10.1212/wnl.48.3_suppl_3.21s. [PMID: 9071266]
R Dixon, C Gillotin, M Gibbens, J Posner, R W Peck. The pharmacokinetics and effects on blood pressure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. British journal of clinical pharmacology. 1997 Mar; 43(3):273-81. doi: 10.1046/j.1365-2125.1997.00547.x. [PMID: 9088582]
E J Seaber, G Ridout, G Layton, J Posner, R W Peck. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide. European journal of clinical pharmacology. 1997; 53(3-4):229-34. doi: 10.1007/s002280050367. [PMID: 9476036]
L L Thomsen, R Dixon, L H Lassen, M Gibbens, M Langemark, L Bendtsen, D Daugaard, J Olesen. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia : an international journal of headache. 1996 Jun; 16(4):270-5. doi: 10.1046/j.1468-2982.1996.1604270.x. [PMID: 8792040]
E Seaber, N On, S Phillips, R Churchus, J Posner, P Rolan. The tolerability and pharmacokinetics of the novel antimigraine compound 311C90 in healthy male volunteers. British journal of clinical pharmacology. 1996 Feb; 41(2):141-7. doi: 10.1111/j.1365-2125.1996.tb00172.x. [PMID: 8838441]
A Dowson. Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura?. European neurology. 1996; 36 Suppl 2(?):28-31. doi: 10.1159/000119101. [PMID: 8791030]